Author

Joel Petersson 1

1 Abbvie Inc, North Chicago, United States

A TREAT TO TARGET APPROACH DECREASES THE RATE OF CD-RELATED ADVERSE OUTCOMES VERSUS A CLINICAL APPROACH IN PATIENTS WITH MODERATE TO SEVERELY ACTIVE CROHN'S DISEASE: DATA FROM CALM

Jean-Frederic Colombel, Remo Panaccione, Peter Bossuyt, Filip Baert, T. Vanásek, Ahmet Danalıoğlu, Gottfried Novacek, Alessandro Armuzzi, Xavier Hebuterne, Simon Travis, Silvio Danese, Walter Reinisch, William Sandborn, Paul Rutgeerts, Daniel W. Hommes, Stefan Schreiber, Ezequiel Neimark, Bidan Huang, Qian Zhou, Wan J Le

ADALIMUMAB LONG-TERM EFFECTIVENESS IN ADALIMUMAB-NAIVE PATIENTS WITH CROHN'S DISEASE: FINAL DATA FROM PYRAMID REGISTRY

Edward V Loftus Jr, Geert R. D'Haens, Walter Reinisch, Jack Satsangi, Remo Panaccione, Sofie Berg, Gabriela Alperovich, Mareike Bereswill, Jasmina Kalabic, Martha Skup, Joel Petersson, Anne M. Robinson

CHARACTERIZATION OF MUCOSAL HEALING WITH ADALIMUMAB TREATMENT IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE FROM EXTEND

Walter Reinisch, Jean-Frederic Colombel, Geert R. D'Haens, William Sandborn, Paul Rutgeerts, Joel Petersson, Samantha Eichner, Annalisa Iezzi, Roopal B Thakkar

CLINICAL BENEFIT OF ADALIMUMAB DOSE ADJUSTMENT FOR PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE IN EXTEND

Jean-Frederic Colombel, Paul Rutgeerts, William Sandborn, Douglas C. Wolf, Walter Reinisch, Gert Van Assche, Samantha Eichner, Joel Petersson, Anne M. Robinson, Roopal B Thakkar

CLINICALLY ADJUSTED VERSUS THERAPEUTIC DRUG MONITORING DOSING REGIMENS WITH ADALIMUMAB IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE: RESULTS FROM THE SERENE-CD MAINTENANCE STUDY

Silvio Danese, William Sandborn, Edward V. Loftus Jr., Stephen B Hanauer, Stefan Schreiber, Laurent Peyrin-Biroulet, Remo Panaccione, Julian Panés, Filip Baert, Jean-Frederic Colombel, Marc Ferrante, Edouard Louis, Alessandro Armuzzi, Sasikiran Goteti, John Liu, Nael M. Mostafa, Thao Doan, Joel Petersson, Anne M. Robinson

CORRELATION BETWEEN ENDOSCOPIC AND HISTOLOGICAL HEALING IN ADULTS WITH MODERATE TO SEVERE CROHN?S DISEASE: DATA FROM EXTEND

Walter Reinisch, Jean-Frederic Colombel, Paul Rutgeerts, Karel Geboes, Geert R. D'Haens, Joel Petersson, Samantha Eichner, Jen-Fue Maa, Anne M. Robinson

DE-ESCALATING THERAPY IN PATIENTS WITH CROHN'S DISEASE RECEIVING ADALIMUMAB: A SUBGROUP ANALYSIS OF THE CALM STUDY

Peter Bossuyt, Geert R. D'Haens, Remo Panaccione, William Sandborn, Walter Reinisch, Simon Travis, Stefan Schreiber, Alessandro Armuzzi, Silvio Danese, Sofie Berg, Joel Petersson, Jen-Fue Maa, Ezequiel Neimark, Jean-Frederic Colombel

EFFECT OF ADALIMUMAB ON CLINICAL AND HEALTH-RELATED QUALITY OF LIFE OUTCOMES BY DISEASE SEVERITY AND PRIOR TUMOUR NECROSIS FACTOR INHIBITOR USE IN PATIENTS WITH ULCERATIVE COLITIS IN A CLINICAL PRACTICE SETTING: SUBGROUP ANALYSES FROM INSPIRADA

Simon Travis, Brian G. Feagan, Laurent Peyrin-Biroulet, Remo Panaccione, Silvio Danese, Joel Petersson, Andreas Lazar, Anne M. Robinson, Naijun Chen, Martha Skup, Wan-Ju Lee

HEALTHCARE RESOURCE UTILIZATION AND QUALITY OF LIFE IN PATIENTS WITH ULCERATIVE COLITIS BY DISEASE SEVERITY: BASELINE DATA FROM ICONIC

Subrata Ghosh, Laurent Peyrin-Biroulet, Francesc Casellas, Ciara O'Shea, Wan Ju Lee, Brandee L Pappalardo, Joel Petersson

High versus standard adalimumab induction dosing regimens in patients with moderately to severely active Crohn's disease: Results from the SERENE-CD induction study

Geert D‘Haens, William Sandborn, Edward Loftus, Jr, Stephen B Hanauer, Stefan Schreiber, Laurent Peyrin-Biroulet, Remo Panaccione, Julian Panés, Jean-Frederic Colombel, Marc Ferrante, Edouard Louis, Alessandro Armuzzi, Qian Zhou, Bidan Huang, Nisha V. Kwatra, Nael M. Mostafa, Thao Doan, Joel Petersson, Alex Song, Anne M.

Item 1 - 10 / 19
1
2